 |
0 Companies | 0 Products |
|
|
0 Products | |
0 Diseases | |
0 Trials |  |
0 News |  |
| «12...1112131415161718192021...2627» |
- Multiplex bead array approach for quantitative profiling of 95 cancer-immunity biomarkers in breast cancer (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_2257;
In these samples we identified markers with significantly altered expression in conditioned media, cell lysates, and tumor cell-derived exosomes from MCF10CA1d tumor cells versus MCF-10A non-tumorigenic mammary epithelial cells as well as triple negative HMT-3522 T4-2 and MDA-MB-231 breast cancer cells. Altogether, our results suggest Luminex-based profiling allows for sensitive and versatile multiplexed analysis of stimulating and inhibitory immune mediators in circulation, tissues, and cell lines which will assist in the discovery of biomarkers and therapeutic targets for cancer interventions.
- BND-22, a first-in-class, anti-ILT2 monoclonal antibody inhibits the immunosuppressive effects of HLA-G and enhances anti-tumor activity of immune cells in preclinical in vitro, ex vivo, and in vivo models (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_2167;
BND-22 offers a differentiated, multi immune cell-based mechanism of action. Safety, tolerability, and anti-tumor activity of BND-22 will be explored in a first-in-human clinical trial in cancer patients with tumor types known to express HLA-G.
- Inhibition of arginase in combination with anti-PDL1 leads to increased infiltration and activation of CD8+ T cells, NK cells, and CD103+ dendritic cells in mouse syngeneic tumor models (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_2152;
Combining ARG inhibitor with anti-PDL1 significantly improved efficacy reaching ~87% TGI in the MCA38-ova model, with 7/10 mice showing tumor regression. In summary, our pre-clinical data demonstrates that an ARG inhibitor in combination with a checkpoint inhibitor can increase plasma and tumor arginine levels and reverse tumor immune-suppression leading to strong immune activation and anti-tumor responses, suggesting arginase inhibitors could provide an opportunity to increase activity of checkpoint inhibitors clinically.
- Targeting breast cancer stem cells with anti-EMP2 immunotoxins delivering granzyme b (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_1716;
Preliminary results using a 4T1 model system produced a significant reduction in tumor burden. Our results suggest that continued development of these agents may be successful at targeting advanced disease.Research supported, in part, by NCI R21 CA234642 and the Clayton Foundation for Research.
- DRP-104 / Dracen Pharma
[VIRTUAL] Broad acting glutamine antagonism remodels the tumor microenvironment, induces distinctive immune modulation, and synergizes with immune checkpoint blockade (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_169;
Combination therapy of DRP-104 with anti-PD-1/PD-L1 achieved significantly enhanced anti-tumor efficacy including long-term durable cures even in checkpoint inhibitor resistant models. This unique and non-overlapping mechanism of action supports clinical development of DRP-104 alone and in combination with PD-1/PD-L-1 checkpoint inhibitors.
- Immuno-oncology panel optimization for imaging mass cytometry and digital image analysis of tumor tissues (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_1662;
IMC is a powerful platform for highly multiplexed detection of protein and cell phenotypes quantification in FFPE samples. Our developed IMC panel and digital image analysis of tissues allow the quantification of immune cells and spatial analysis of the tumor tissue microenvironment.
- Identification of differential immune landscapes in high-grade serous ovarian tumors of high-risk patients by imaging mass cytometry (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_1652;
This may have clinical implications; but, furthermore, may suggest novel approaches to therapy. Overall, this study shows that IMC provides a powerful and comprehensive approach to evaluating the cellular phenotype and spatial interrelationships of the tumor immune environment.
- Mutational analysis of colon tumors from African American patients and potential association with cancer disparities (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_1613;
We also observed divergence in the mutational profiling between the groups, including numerous genes that are indicative of prognosis, treatment and outcomes in colon cancer. As such, these deficits could be mitigated through population-specific therapeutic approaches.
- EMT-6 tumor conditioned Breg cells inhibit NK cell proliferation and cytotoxic activity (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_1605;
EMT-6 TIL-B or normal B cells conditioned by EMT-6 coculture acquire an NK suppressive phenotype which inhibits NK cell activation, proliferation, degranulation and cytotoxic function. Targeting of Breg-NK interactions may improve anti-tumor immune response.
- Immuno-reactive cancer organoid models to examine immune checkpoint blockade efficacy (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_117;
This will allow us to modulate facets of the tumor in the organoid system including cancer type, tumor cell mutations, biochemical signals, and physical properties of the microenvironment. We can then observe the impacts of these changes on immunotherapy efficacy to determine what factors could potentially be contributing to differences in patient sensitivity.
- Tertiary lymphoid structures features associate with outcome in non-small cell lung carcinoma (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_1081;
mTLSs are associated with reduced IT infiltration by PD-1+ TILs. Taken together, germinal center development in mTLSs might convey a protective immune response due to immuno-dominant neoantigen presentation.
- Lrg1 blockade modulates the tumor immune microenvironment and improves the efficacy of cancer therapeutics (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_1077;
Histological analysis revealed that the combination therapy was associated with a significantly higher number of activated CD8+ T cells, together with enhanced expression of Granzyme B. Current studies are investigating whether the observed boost in cytotoxic T cell density and functionality is a direct consequence of vessel normalization or whether LRG1 blockade is able to modulate the tumour immune microenvironment at different levels: for example, FACS analysis of tumour-infiltrating leukocytes revealed a reduction in the percentage of regulatory T cells after dual therapy, while histological analysis suggested an increase in the number of M1 macrophages. These data show that LRG1 blockade orchestrates a shift in the tumour microenvironment from being immune silent to immune active and, therefore, might represent a novel tool to enhance the efficacy of cancer therapies.
- Development of a cytotoxic fusion protein targeting VEGF receptors with improved cytotoxicity, stability and pharmacokinetics (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_1061;
In summary, the GrB-Fc-VEGF121 produced in HEK293E cells is active and has significant potential as a targeted therapeutic. Research conducted, in part, by the Clayton Foundation for Research.
- A novel, completely human fusion construct containing active Granzyme B efficiently kills Folate Receptor alpha positive tumor cells (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_1049;
Immunofluorescence and confocal studies to examine the time course of internalization and the pro-apoptotic events triggered by these agents are under examination and will be presented. Research conducted, in part, by the Clayton Foundation for Research.
- RG6146 / Roche
Sensitizing cancer cells to TNF induced cell death by the BET-inhibitor RG6146 (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_1006;
Even though treatment of this co-culture with the CEATCB alone increased bystander killing of cancer cells expressing low CEA levels, addition of RG6146 significantly enhanced this effect.We used syngeneic recipient mice to validate our findings in vivo. While single agent treatment of CEATCB or BETi decreased tumor growth, the combination of both molecules caused tumor regression.Taken together this data establishes a paradigm where BETi can rewire NF-κB signaling, leading to enhanced sensitivity to cytotoxic lymphocyte-derived TNF and therapeutically augmenting the anti-tumor activity of IO agents.
- Excessive ROS in ovarian cancer cells impairs anti-tumor capacities of immune cells through exosomal miR-155/PD-L1 pathway (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_1004;
In conclusion, our study reveals a novel mechanism underlying PD-L1 expression in EOC. Ovarian cancer cells with excessive ROS levels release exosomes that mediate the interaction between cancer cells and immune cells; it is this interplay that produces an immunosuppressive tumor microenvironment by upregulation of PD-L1 in macrophages, and eventually contributes to the progress of EOC through the ROS/miR-155-5p/PD-L1 pathway.
- Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
[VIRTUAL] PROGNOSTIC VALUE OF TISSUE-INFILTRATING IMMUNE CELLS IN TUMOR MICROENVIRONMENT OF FOLLICULAR LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS () - May 16, 2020 - Abstract #EHA2020EHA_2287;
A high degree of CD68+ macrophage infiltration at diagnosis was a negative prognostic factor for OS, but was associated with good prognosis in the rituximab-era subgroup...The HR in the TTT analyses suggested that high CD68+ LAM numbers, diffuse pattern of FOXP3+ Treg cells and PD1+ cells, and high PD-L1 cell numbers are adverse factors leading to early transformation (Figure). Conclusion Multiple non-neoplastic cells in the FL microenvironment play critical and different roles in prognosis, and further exploration of the related mechanisms may contribute to the development of FL therapeutics against the tumor microenvironment.
- Adcetris (brentuximab vedotin) / Seattle Genetics, Takeda, doxorubicin hydrochloride / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] PRIMARY CUTANEOUS GAMMA-DELTA T-CELL LYMPHOMA: SUCCESSFUL USE OF BRENTUXIMAB VEDOTIN ASSOCIATED WITH CHEMOTHERAPY AS BRIDGING THERAPY TO HAPLOIDENTICAL TRANSPLANT () - May 16, 2020 - Abstract #EHA2020EHA_2138;
He was initially treated with a scheme of multiagent CTX consisting of Cyclophosphamide, Adriamycin, Vincristine and Etoposide (CHOEP), but after two cycles of treatment the patient was reevaluated because of a persistent fever...As a second line, considering that the tumor was CD30 positive, we decided to add Bv to Etoposide, Citarabine and Cisplatin (Br-ESHAP) and further consolidation with allogeneic hematopoietic stem cell transplant (HSCT)... a clinical and metabolic CR, allowing to face the transplant without a trace of disease.
- [VIRTUAL] PD-1- AND TIM-3-EXPRESSING T CELLS INCREASE PROLIFERATIVE ABILITY AND PARTIALLY RETAIN FUNCTIONAL PROPERTIES AT EARLY POST-TRANSPLANT PERIOD IN MULTIPLE MYELOMA PATIENTS () - May 16, 2020 - Abstract #EHA2020EHA_1502;
Proliferative ability at early post-transplant period increased even in dysfunctional TIM-3+ T cell subsets. The Russian Science Foundation under grant № 18-75-00050 supports this work.
- [VIRTUAL] AUTOLOGOUS NK CELL-BASED IMMUNOTHERAPY FOR MAINTENANCE TREATMENT OF MULTIPLE MYELOMA () - May 16, 2020 - Abstract #EHA2020EHA_1486;
In summary, the present study demonstrates that autologous NK cell-based immunotherapy is feasible and demonstrate clinical applicability with efficacy responses in an upfront autologous HSCT-setting in MM. Conclusion The treatment strategy opens up for usage of autologous NK cells in clinical settings where patients are not readily eligible for allogeneic NK cell-based treatments, including MRD and maintenance treatment in MM and other forms of malignancies.The treatment strategy opens up for usage of autologous NK cells in clinical settings where patients are not readily eligible for allogeneic NK cell-based treatments, including MRD and maintenance treatment in MM and other forms of malignancies.
- [VIRTUAL] THE ROLE OF LNCRNA-AF117829.1 IN THE IMMUNOPATHOGENESIS OF CD8+ T CELLS IN PATIENTS WITH SEVERE APLASTIC ANEMIA () - May 16, 2020 - Abstract #EHA2020EHA_1011;
LncRNA-AF117829.1 was selected and verified in vitro, which can promote CD8+ T cell by upregulating the expression of target gene RIP2. These results maybe helpful to further explore the molecular mechanism of immune pathogenesis of SAA and provided potential targets for diagnosis and treatment of SAA.
- [VIRTUAL] THE ROLE OF DECREASED TIM3 EXPRESSION OF NK CELLS IN THE IMMUNE PATHOGENESIS OF SEVERE APLASTIC ANEMIA () - May 16, 2020 - Abstract #EHA2020EHA_1002;
After TIM3—NK cell reinfusion, the general condition, blood cell count and bone marrow cell count of SAA mice were improved, and the combined treatment of CsA was more effective. It may further clarify the immune pathogenesis of SAA and provide a new treatment target to improve the efficacy of SAA treatment.
- [VIRTUAL] DIACYLGLYCEROL KINASE Z DEFICIENCY TRIGGERS EARLY SIGNS OF APLASTIC ANEMIA IN MICE () - May 16, 2020 - Abstract #EHA2020EHA_999;
Conclusion Our results correlate to those reported in patients of AA, suggesting that limited expression/function of DGKζ could contribute to the onset of AA and BM destruction. This study identifies the BM of DGKζ deficient mice as a niche of enhanced T cell responses and could serve as a novel clinical model to study the factors and mechanisms that predispose to AA development.
- [VIRTUAL] TP53 MUTATED AML IS ASSOCIATED WITH AN IMMUNE DYSFUNCTION () - May 16, 2020 - Abstract #EHA2020EHA_744;
TP53mut AML is associated with dysfunctional T cells. These findings highlight potential mechanisms of immune evasion in TP53mut AML.
- | Journal: Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054. (Pubmed Central) - May 14, 2020
Proof concept and preclinical results show anti-PD-1/LAG-3 bispecific antibodies bind and are internalized by CD4+ T cells thereby increasing their effector functions (release of Granzyme B and INF-γ) in the presence of tumor cells, and completely suppress tumors in a murine model.Expert opinion: Anti-PD-1/LAG-3 bispecific antibodies of the US2018326054 patent are new in a general concept, but treatment data is only shown for pancreatic carcinoma. The results to be obtained in future clinical trials of safety and efficacy could conclude whether these bispecific anti-PD-1/LAG-3 antibodies will be useful in a cancer treatment scheme.
- || Review, Journal: The immune response to influenza in older humans: beyond immune senescence. (Pubmed Central) - May 14, 2020
Current influenza vaccines provide only a weak stimulus to this arm of the adaptive immune response and rely on re-stimulation of CD8 T cell memory related to prior exposure to influenza virus. Efforts to improve vaccine effectiveness in older adults will be fruitless until CD8 responses take center stage.
- | Journal: CD8CD28T-cells: Key cytotoxic players impacting disease pathogenesis in chronic HBV infection. (Pubmed Central) - May 13, 2020
Immunofluorescence staining identified greater intrahepatic incidence of CD8CD28T-cells but decline in CD4T-cells in CHB than IC. Collectively, CD8CD28T-cells demonstrated differential distribution and phenotypic/functional skewing in different CHI phases and contribute to disease progression by Perforin-Granzyme- or IFN-γ-TNF-α-mediated cytotoxicty while restraining antiviral immunity through NKG2D-dependant HBV-specific CD4T-cell depletion.
- | Preclinical, Journal, PD(L)-1 Biomarker, IO Biomarker: In-situ vaccination using focused ultrasound heating and anti-CD-40 agonistic antibody enhances T-cell mediated local and abscopal effects in murine melanoma. (Pubmed Central) - May 13, 2020
Additionally, the local FUS40 prevented adverse liver toxicities in the treated mice. Our study suggests that combined FUS and CD-40 can enhance T-cell and macrophage functions to aid effective melanoma immunotherapy.
- | Journal: T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes. (Pubmed Central) - May 11, 2020
We apply T-Scan to discover new viral antigens, perform high-resolution mapping of TCR specificity, and characterize the reactivity of a tumor-derived TCR. T-Scan is a powerful approach for studying T cell responses.
- MTV273 / Novartis
Exhaustion and Activation Status in Apheresed T Cells Correlate with Response to Anti-BCMA CAR T Cell Therapy in Myeloma () - May 9, 2020 - Abstract #ASGCT2020ASGCT_97;
This cluster also dominated the CD4 T-cell repertoire in the first four months after infusion in the four responding patients.In conclusion, our data suggest that strategies to promote expression of Eomes and central memory function and reduce exhaustion in BCMA CAR T-cells will enhance clinical activity. Further, these results underscore the “self-sustaining” feature of successful CAR T-cell therapies in myeloma.
- CST-101 / NantKwest
Il2 and Il21 Chimeric Signaling in Nk92Cirb21 Enhances Anti-Tumor Activity and Safety of Live Nk92 Cells for Cancer Immunotherapy () - May 9, 2020 - Abstract #ASGCT2020ASGCT_60;
The growth and antitumor activity of live NK92CIRB21 cells were further enhanced by synergy with CAR-EGFR. Our findings suggest that artificial chimeric signaling from IL2 and IL21 receptors platform offers enhanced efficacy and safety allowing the use of long-lived NK92 cells for cancer Immunotherapy.
- || Clinical, Journal, IO Biomarker: Impairment of Vα24-Jα18Vβ11 natural killer T cells in adult acute lymphoblastic leukemia patients. (Pubmed Central) - May 9, 2020
In addition, we observed a positive correlation between the frequency of IL-21R type I NKT cells and the frequencies of IFN-γ-, granzyme B-, and perforin-expressing circulating CD8 T cells in adult B-cell ALL patients directly ex vivo. Overall, this study identified an IL-21-related impairment in type I NKT cells from adult B-cell ALL patients.
- | Journal: Disrupted regulation of serpinB9 in circulating T cells is associated with an increased risk for post-transplant skin cancer. (Pubmed Central) - May 9, 2020
Also, a significant difference in serpinB9 protein expression between cSCC patients and non-cSCC patients was observed. Concluding that disturbed regulation of serpinB9 in circulating T cells represents a novel risk factor for post-transplant cSCC in kidney transplant recipients.
- | Journal: Aged human skin accumulates mast cells with altered functionality which localise to macrophage and VIP nerve fibres. (Pubmed Central) - May 7, 2020
Concluding that disturbed regulation of serpinB9 in circulating T cells represents a novel risk factor for post-transplant cSCC in kidney transplant recipients. Hence, in photoprotected skin, we observe an accumulation of MCs with increasing age; these MCs have both altered functionality and distribution within the skin which supports a role for these cells in altered tissue homeostasis during ageing.
- | tamoxifen / Generic mfg.
Journal: Blockade of NKG2D/NKG2D Ligand Interaction Attenuated Cardiac Remodeling after Myocardial Infarction. (Pubmed Central) - May 7, 2020
The interaction between immune cells and cardiomyocytes via NKG2D/NKG2DL induces cardiomyocyte death, exacerbating cardiac remodeling after MI. The blockade of NKG2D/NKG2DL interaction could be a promising therapeutic strategy against HF.
- || Clinical, Journal: Chronic Hepatitis B Infection Alters Peripheral Immune Response in Women with Reproductive Failure. (Pubmed Central) - May 7, 2020
Chronic HBV infection alters peripheral immune responses by upregulating B cells frequency, decreasing CD3 CD4 helper T cells, and decreasing peripheral NK function and toxicity. These may influence pregnancy outcome on HBV infected patients, and the pathogenesis of HBV infection on pregnancy outcome deserves to be further studied.
- | Journal: CD4 resident memory T cells dominate immunosurveillance and orchestrate local recall responses. (Pubmed Central) - May 7, 2020
Functionally, mucosal CD4 T reactivation locally triggered both chemokine expression and broad immune cell activation. Thus, residence provides a dominant mechanism for regionalizing CD4 T cell immunity, and location enforces shared transcriptional, phenotypic, and functional properties with CD8 T cells.
- || Clinical, Journal: Simultaneous use of natural adjuvants and cell penetrating peptides improves HCV NS3 antigen-specific immune responses. (Pubmed Central) - May 7, 2020
Thus, residence provides a dominant mechanism for regionalizing CD4 T cell immunity, and location enforces shared transcriptional, phenotypic, and functional properties with CD8 T cells. No abstract available
- | Journal: Distinctive phenotypes and functions of innate lymphoid cells in human decidua during early pregnancy. (Pubmed Central) - May 6, 2020
Acquisition of KIR correlates with higher granzyme B levels and increased chemokine production in response to KIR activation, suggesting a link between increased granule content and dNK1 responsiveness. Our analysis shows that dILCs are unique and provide specialised functions dedicated to achieving placental development and successful reproduction.
- | ABT-737 / AbbVie
Journal, IO Biomarker: Hantavirus inhibits apoptosis by preventing mitochondrial membrane potential loss through up-regulation of the pro-survival factor BCL-2. (Pubmed Central) - May 6, 2020
Overall, we here provide a tentative mechanism by which hantaviruses protect infected cells from intrinsic apoptosis at the mitochondrial level by inducing an increased expression of the pro-survival factor BCL-2, thereby preventing MOMPs and subsequent activation of caspases. The variety of mechanisms used by hantaviruses to ensure survival of infected cells likely contribute to the persistent infection in natural hosts and may play a role in immunopathogenesis of HFRS and HPS in humans.
- | Biomarker, Journal, IO biomarker: Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. (Pubmed Central) - May 6, 2020
Updated results from a first-in-dog clinical trial of palliative RT and autologous NK cell immunotherapy for OSA illustrate the translational relevance of companion dogs for novel cancer therapies. Similar to human studies, analyses of immune markers from canine serum, PBMCs, and tumor tissue are feasible and provide insight into potential biomarkers of response and resistance.
- || Biomarker, Retrospective data, Review, Journal: The prognostic role of NK cells and their ligands in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis. (Pubmed Central) - May 5, 2020
Some studies implied the opposite, indicating the fine balance between pro- and anti-tumor functions of NK cells. Future studies using homogeneous patient cohorts regarding tumor subsite and treatment modality, are necessary to further provide insight into the prognostic role of NK cells.
- | Journal, IO Biomarker: B7-H3 inhibits the IFN-γ-dependent cytotoxicity of Vγ9Vδ2 T cells against colon cancer cells. (Pubmed Central) - May 5, 2020
More importantly, blocking the B7-H3 function significantly enhanced the cytotoxicity of Vδ2 T cells against colon cancer cells in vivo. Therefore, the inhibition or blockade of B7-H3 is a potential immunotherapeutic approach for colon cancer.
- | Journal: Effects of Beta-Blockers on Melanoma Microenvironment and Disease Survival in Human. (Pubmed Central) - May 2, 2020
An exposure to beta-blockers is associated with a better outcome in our cohort of melanoma patients. This study shows the association between an exposure to wide spectrum beta-blockers and markers of an effective anti-tumor immune response as well as the protective effect of beta-blockers in human melanoma patients.
- | Preclinical, Journal: Chronic infusion of interleukin-17 promotes hypertension, activation of cytolytic natural killer cells, and vascular dysfunction in pregnant rats. (Pubmed Central) - May 1, 2020
Finally, vascular reactivity of uterine arteries was significantly impaired in response to IL-17 infusion. The results of this study suggest that IL-17 plays a significant role in the activation of cNK cells during pregnancy.
- Opdivo (nivolumab) / Ono Pharma, BMS, pegilodecakin (LY3500518) / Eli Lilly
[VIRTUAL] Randomized phase II study of nivolumab (N) alone versus with pegilodecakin (PEG) in combination with N in patients (pts) with post-platinum immunotherapy-naive stage IV non-small cell lung cancer (NSCLC) and no or low PD-L1 expression (CYPRESS 2). () - Apr 29, 2020 - Abstract #ASCO2020ASCO_5687;
P1
Despite evidence of biological effect, adding PEG to N did not lead to improvement in ORR, PFS, or OS in post-platinum advanced NSCLC with no or low PD-L1 expression. PEG+N arm demonstrated expected safety profile but overall higher toxicity compared to nivolumab alone.
- [VIRTUAL] Multipeptide vaccine to prevent epithelial ovarian cancer relapse by microenvironment immunomodulation. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3643;
Treating EOC patients in remission in zones hardly explored previously in order to potentially improve the activation of antigen-specific Th1 and CD8 cells with specific peptides seems promising as a feasible and safe approach to prevent EOC relapse. Research Funding: Sonora Cancer Research Center Foundation from Ciudad Obregon, Sonora, Mexico.
- Phenoxodiol (idronoxil) / MEI, cisplatin / Generic mfg., Veyonda (idronoxil) / Noxopharm
[VIRTUAL] Effect of idronoxil combined with cisplatin on refractory immune responses in nasopharyngeal carcinoma. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3561;
Moreover, the ability of IDX to modulate T cell populations indicates the drug’s potential to enhance the efficacy of current chemotherapy treatments in NPC by upregulating cellular trafficking to the cancer cell. Research Funding: Bridging grant from Australian Academy of Technology & Engineering
- [VIRTUAL] The potential target of double negative T cells in cancer immunotherapy. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3555;
Although the function of DNTs was still not well elucidated, the accumulation of DNT cells in tumor microenvironment suggests DNTs could be a potential target for cancer immunotherapy. Research Funding: None
- paclitaxel / Generic mfg.
[VIRTUAL] Impact of chemotherapy alone or in combination with an anti-angiogenic on the immune tumor microenvironment (TME) of ovarian cancer: Data from the randomized CHIVA trial (a GINECO –GINEGEPS study). () - Apr 29, 2020 - Abstract #ASCO2020ASCO_2599;
However this change seems to be mainly mediated by platinum+paclitaxel chemotherapy rather than the anti-angiogenic tyrosine kinase inhibitor nintedanib. Research Funding: Maria Pia Award